Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) does about 38.62M shares in volume on a normal day but saw 28948388 shares change hands in the recent trading day. The company now has a market cap of 33.04M USD. Its current market price is $0.19, marking a decrease of -6.95% compared to the previous close of $0.20. The 52 week high reached by this stock is $22.14 whilst the lowest price level in 52 weeks is $0.12.
Tonix Pharmaceuticals Holding Corp (TNXP) has a 20-day trading average at $0.1535 and the current price is -99.14% off the 52-week high compared with 61.02% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.1511 and its 200-day simple moving average is $3.4829. If we look at the stock’s price movements over the week, volatility stands at 24.27%, which decreases to 13.16% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 61.22 to suggest the stock is neutral.
The consensus objective for the share price is $26.00, suggesting that the stock has a potential upside of 99.27% over the period.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 4 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
ROTH Capital upgraded the stock to “Buy” from Neutral on April 18, 2019 at a price target of $4. ROTH Capital upgraded its price target at $6.
The current price level is 23.80%, 25.72%, and -94.54% away from its SMA20, SMA50, and SMA200 respectively, with the TNXP price moving below the 50-day SMA on current market day. Tonix Pharmaceuticals Holding Corp (TNXP) stock is up 44.93% over the week and 18.38% over the past month. Its price is -98.53% year-to-date and -98.77% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/30/2024, with the company’s earnings per share (EPS) of 17.6 above consensus estimates by 61.6. The company’s next earnings report forecasts estimating quarterly EPS at -7.68 and -35.52 for whole year. Expected sales for next quarter are $4.1M, which analysts say will come at $12.55M for the current fiscal year and next year at $15.62M. In addition, estimates put the company’s current quarterly revenue at an average of $3.2M.
To reach the target analysts have set, the stock logically needs to grow 99.27 percent from here.
Outstanding shares total 186.89M with insiders holding 0.17% of the shares and institutional holders owning 0.23% of the company’s common stock. The company has a return on investment of -169.47% and return on equity of -138.69%. The beta has a value of 2.24. Price to book ratio is 0.40 and price to sales ratio is 2.93.
